

Dear Mr. Josephy:

I am pleased to inform you that the Ministry has concluded its negotiations with the manufacturer and effective December 28, 2011, the funding criteria for Gleevec for GIST patients has been revised to extend the reimbursement to patients with Adjuvant GIST. I have included the full funding criteria for Gleevec for Adjuvant GIST below for your ease of reference.

- Patients are at intermediate to high risk of recurrence following complete resection (using Miettinen relapse risk criteria, risk >/20%); AND
- The pathology has been confirmed with c-kit positivity.

Dosing is 400mg daily.

Funding: 1 year

Note, the funding period is for 1 year based on the evidence that was submitted by the manufacturer. We have requested that they provide the CED with evidence to demonstrate effect beyond the 1 year time frame and we indicated that we will review the information as soon as possible.

Please note that this information is available on the ministry website at:

http://www.health.gov.on.ca/english/providers/program/drugs/pdf/frequently_requested_drugs.pdf

I trust this information is helpful and would like to thank you for taking the time to write on this matter.

Sincerely,

Brent Fraser
Director, Drug Program Services
Ministry of Health and Long-Term Care
Ontario